Hypersensitivity & infusion-related reactions. Not to be administered as IV push or bolus. Not to be initiated in patients w/ any clinically important active infections until resolved or adequately treated. May increase risk of infections. Immediate, life-threatening GPP flare or flare requiring intensive care treatment. New-onset peripheral neuropathy symptoms. Evaluate for TB infection prior to initiation. Not to be used in combination w/ other GPP treatments eg, systemic immunosuppressants. Not to be administered w/ live vaccines for at least 16 wk after treatment. Avoid use during pregnancy. Lactation. Childn <18 yr.
Sign Out
